ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

NCT00439192 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

275

Enrollment

INDUSTRY

Sponsor class

Stopped side effect profile did not match expectations

Conditions

Overactive Bladder
Urinary Incontinence

Interventions

DRUG: ELB245
DRUG: Tolterodine

Sponsor

elbion AG